AGEN
AGENUS INC
$3.14
-2.79%
$130.8M
No data for this timeframe.
Vol
Market Cap$130.8M
Cap SizeMicro Cap
Inst. Holders8 funds
Inst. Value$12.0M
Inst. Activity1 buys / 2 sells
SEC Reports3
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001098972·Prev Close $3.23
Recent Activity
Jun 8, 2026
SEC
Agenus Inc. and its CEO Garo Armen had their answers stricken and default judgment entered against them in a breach-of-c
COURT-RULING — Impact 7/10
May 29, 2026
Insider
ARMEN GARO H sold 4,644 shares
See Remarks @ $3.50 ($16.3K)
May 18, 2026
short_volume
Short Volume: AGEN — 62.1% short (0.3M / 0.5M)
Short: 320,235 | Exempt: 10,247 | TRF Vol: 515,645 | Short Ratio: 62.1% | Off-exchange volume (dark
May 15, 2026
Insider
ARMEN GARO H sold 4,540 shares
See Remarks @ $3.58 ($16.3K)
May 13, 2026
SEC
Agenus filed a DEFA14A supplement correcting a material error in its April 30 proxy statement: the number of options eli
DEFA14A — Impact 4/10
May 11, 2026
SEC
Agenus reported Q1 2026 total revenue of $33.7M (up from $24.1M YoY) and net income of $39.2M vs a net loss of $26.4M in
8-K — Impact 7/10
May 1, 2026
Insider
ARMEN GARO H sold 4,233 shares
See Remarks @ $3.84 ($16.3K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
543,546 shares ($1.7M)
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$15.50 (Sep 2025)
Current $3.11
Low $8.00
Median $15.50
High $23.00
2 analysts
$8.00
$23.00
Analyst Ratings
2Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 10, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 28, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jun 4, 2025 | Baird | MAINTAIN | Neutral → Neutral |
| Jun 4, 2025 | HC Wainwright & Co. | UPGRADE | Neutral → Buy |
| May 13, 2025 | HC Wainwright & Co. | REITERATE | Neutral → Neutral |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.40 | $-0.40 — $-0.40 | 60% YoY | 1 |
| Next Q | $0.90 | $0.90 — $0.90 | 177% YoY | 1 |
| Current FY | $0.50 ▼ -74.4% | $0.50 — $0.50 | 120% YoY | 1 |
| Next FY | $-2.30 ▼ -29.2% | $-2.30 — $-2.30 | -560% YoY | 1 |
Latest Reports
BEARISH
COURT-RULING
7/10
Agenus Inc. and its CEO Garo Armen had their answers stricken and default judgment entered against them in a breach-of-c
Jun 8, 2026
NEUTRAL
DEFA14A
4/10
Agenus filed a DEFA14A supplement correcting a material error in its April 30 proxy statement: the number of options eli
May 13, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $8.9M | — |
| RENAISSANCE TECHNOLOGIES LLC | $1.7M | DOUBLED |
| MORGAN STANLEY | $895.5K | TRIM |
| TWO SIGMA INVESTMENTS, LP | $367.7K | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $47.3K | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | ARMEN GARO | A | $16.3K |
| May 15, 2026 | ARMEN GARO | A | $16.3K |
| May 1, 2026 | ARMEN GARO | A | $16.3K |
| Apr 24, 2026 | Wright Timothy | A | $0.00 |
| Apr 24, 2026 | ARMEN GARO | A | $0.00 |
8 institutional holders with $12.0M total value (3,820,517 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN. Net selling activity: 2 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,830,736 | $8.9M | 74.1% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 543,546 | $1.7M | 14.2% | DOUBLED +721.1% |
| 3 | MORGAN STANLEY | 285,198 | $895.5K | 7.5% | TRIM -48.1% |
| 4 | TWO SIGMA INVESTMENTS, LP | 117,117 | $367.7K | 3.1% | NEW |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 15,061 | $47.3K | 0.4% | NEAR_EXIT -76.4% |
| 6 | BANK OF AMERICA CORP /DE/ | 13,246 | $41.6K | 0.3% | NEAR_EXIT -96.4% |
| 7 | WELLS FARGO & COMPANY/MN | 10,184 | $32.0K | 0.3% | ADD +35.1% |
| 8 | FMR LLC | 5,429 | $17.0K | 0.1% | NEAR_EXIT -84.4% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 66,200 | 543,546 | +721.1% | $1.7M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 549,126 | 285,198 | -48.1% | $895.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 369,314 | 13,246 | -96.4% | $41.6K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 778,005 | 549,126 | -29.4% | $2.1M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 102,353 | — | $394.1K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 66,200 | — | $254.9K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | ADD | 9,859 | 13,321 | +35.1% | $51.3K | 2025-Q3 |
| MORGAN STANLEY | ADD | 419,763 | 778,005 | +85.3% | $3.6M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 200,351 | 420,678 | +110.0% | $1.9M | 2025-Q2 |
| UBS Group AG | TRIM | 141,345 | 84,979 | -39.9% | $388.4K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEAR_EXIT | 63,685 | 15,061 | -76.4% | $68.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 23,406 | 9,859 | -57.9% | $45.1K | 2025-Q2 |
| FMR LLC | NEAR_EXIT | 37,069 | 5,784 | -84.4% | $26.4K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 149,808 | 84,500 | -43.6% | $127.2K | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 47,954 | 63,685 | +32.8% | $95.8K | 2025-Q1 |
| FMR LLC | TRIM | 91,649 | 37,069 | -59.6% | $55.8K | 2025-Q1 |
| MORGAN STANLEY | ADD | 276,413 | 397,736 | +43.9% | $1.1M | 2024-Q4 |
| UBS Group AG | DOUBLED | 10,053 | 117,330 | +1067.1% | $321.5K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 35,984 | 23,275 | -35.3% | $63.8K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 168,546 | 0 | -100.0% | $0.00 | 2024-Q4 |
| MORGAN STANLEY | TRIM | 408,210 | 276,413 | -32.3% | $1.5M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 55,954 | — | $306.6K | 2024-Q3 |
8 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | ARMEN GARO H | See Remarks | A | 4,644 | $3.50 | $16.3K |
| May 15, 2026 | ARMEN GARO H | See Remarks | A | 4,540 | $3.58 | $16.3K |
| May 1, 2026 | ARMEN GARO H | See Remarks | A | 4,233 | $3.84 | $16.3K |
| Apr 24, 2026 | Wright Timothy | Director | A | 105,000 | $0.00 | $0.00 |
| Apr 24, 2026 | ARMEN GARO H | See Remarks | A | 1,000,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Corvese Brian | Director | A | 210,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Hirsch Susan B | Director | A | 105,000 | $0.00 | $0.00 |
| Apr 24, 2026 | Buell Jennifer | See Remarks | A | 300,000 | $0.00 | $0.00 |
| Apr 24, 2026 | O'Day Steven J | Chief Medical Officer | A | 70,000 | $0.00 | $0.00 |
| Apr 24, 2026 | HARRISON THOMAS L | Director | A | 122,500 | $0.00 | $0.00 |
| Apr 24, 2026 | Charette Austin | Principal Accounting Officer | A | 5,000 | $0.00 | $0.00 |
| Apr 17, 2026 | ARMEN GARO H | See Remarks | A | 3,403 | $4.79 | $16.3K |
| Apr 3, 2026 | ARMEN GARO H | See Remarks | A | 4,629 | $3.33 | $15.4K |
| Apr 1, 2026 | HARRISON THOMAS L | Director | A | 9,228 | $3.32 | $30.6K |
| Apr 1, 2026 | Wright Timothy | Director | A | 2,448.256 | $0.00 | $0.00 |
| Mar 20, 2026 | ARMEN GARO H | See Remarks | A | 3,983 | $3.71 | $14.8K |
| Mar 6, 2026 | ARMEN GARO H | See Remarks | A | 4,994 | $2.96 | $14.8K |
| Feb 20, 2026 | ARMEN GARO H | See Remarks | A | 4,829 | $3.06 | $14.8K |
| Feb 6, 2026 | ARMEN GARO H | See Remarks | A | 5,027 | $2.94 | $14.8K |
3 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
COURT-RULING
7/10
Agenus Inc. and its CEO Garo Armen had their answers stricken and default judgment entered against t
Jun 8, 2026
NEUTRAL
DEFA14A
4/10
Agenus filed a DEFA14A supplement correcting a material error in its April 30 proxy statement: the n
May 13, 2026
BULLISH
8-K
7/10
Agenus reported Q1 2026 total revenue of $33.7M (up from $24.1M YoY) and net income of $39.2M vs a n
May 11, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Sep 2025): 88% buy across 8 analysts — 2 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$15.50 mean target (Sep 2025)
$8.00 Low
$23.00 High
| Metric | Value |
|---|---|
| Current Price | $3.11 |
| Target Low | $8.00 |
| Target Mean | $15.50 |
| Target Median | $15.50 |
| Target High | $23.00 |
| # Analysts | 2 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.40 | $-0.40 | $-0.40 | 60.0% | — | 0↑ 1↓ | $0.0B | 32.3% | 1 |
| Next Q 2026-09-30 |
$0.90 | $0.90 | $0.90 | 177.4% | — | 0↑ 1↓ | $0.0B | 13.3% | 1 |
| Current FY 2026-12-31 |
$0.50 | $0.50 | $0.50 | 119.9% | -74.4% | 1↑ 0↓ | $0.2B | 61.7% | 1 |
| Next FY 2027-12-31 |
$-2.30 | $-2.30 | $-2.30 | -560.0% | -29.2% | 1↑ 0↓ | $0.1B | -28.8% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.400 | |
| 7d ago | $0.000 | -0.400 |
| 30d ago | $0.000 | -0.400 |
| 60d ago | $0.000 | -0.400 |
| 90d ago | $0.000 | -0.400 |
9 analyst firms have rated this stock: 2 upgrades, 4 downgrades, 9 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 10, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 28, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 4, 2025 | Baird | MAINTAIN | Neutral | Neutral |
| Jun 4, 2025 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| May 13, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| May 13, 2025 | Baird | MAINTAIN | Neutral | Neutral |
| Apr 30, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 18, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 12, 2025 | Baird | MAINTAIN | Neutral | Neutral |
| Mar 12, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Jan 22, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Dec 5, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Nov 29, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Nov 12, 2024 | HC Wainwright & Co. | MAINTAIN | Neutral | Neutral |
| Aug 14, 2024 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Jul 19, 2024 | Jefferies | DOWNGRADE | Buy | Hold |
| Jul 18, 2024 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jun 28, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 24, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 7, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 18, 2024 | B. Riley Securities | MAINTAIN | Buy | Buy |
| Mar 14, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Aug 8, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jul 3, 2023 | EF Hutton | REITERATE | Buy | Buy |
| Jul 3, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 6, 2023 | Baird | INITIATE | — | Outperform |
| Jun 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2023 | EF Hutton | REITERATE | Buy | Buy |
| May 26, 2023 | EF Hutton | REITERATE | Buy | Buy |
| Mar 29, 2023 | B. Riley Securities | REITERATE | — | Buy |
| Mar 28, 2023 | EF Hutton | REITERATE | — | Buy |
| Mar 15, 2023 | EF Hutton | REITERATE | — | Buy |
| Dec 22, 2022 | EF Hutton | INITIATE | — | Buy |
| Dec 8, 2022 | EF Hutton | INITIATE | — | Buy |
| Mar 2, 2022 | HC Wainwright & Co. | MAINTAIN | — | Buy |
| Dec 16, 2021 | HC Wainwright & Co. | INITIATE | — | Buy |
| Apr 22, 2019 | B. Riley Securities | INITIATE | — | Buy |
| Oct 28, 2016 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jul 29, 2016 | Jefferies | MAINTAIN | — | Buy |
| Mar 11, 2016 | Maxim Group | UPGRADE | Hold | Buy |
| Mar 9, 2016 | JMP Securities | MAINTAIN | — | Market Outperform |
| Oct 27, 2015 | Maxim Group | DOWNGRADE | Buy | Hold |
| Jun 10, 2015 | Oppenheimer | INITIATE | — | Outperform |
| Apr 3, 2014 | McNicoll Lewis Vlak | MAINTAIN | — | Buy |
| Feb 24, 2014 | HC Wainwright & Co. | INITIATE | — | Buy |
| Jun 18, 2013 | Maxim Group | INITIATE | — | Buy |
| Apr 2, 2013 | JMP Securities | INITIATE | — | Market Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| May 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Apr 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Mar 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Feb 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% | |
| Jan 1, 2026 | 2 | 5 | 2 | 0 | 0 | 78% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
short_volume
Short Volume: AGEN — 62.1% short (0.3M / 0.5M)
Short: 320,235 | Exempt: 10,247 | TRF Vol: 515,645 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
May 11, 2026
earnings_calendar
AGEN Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: AGEN — 65.3% short (0.7M / 1.1M)
Short: 705,825 | Exempt: 39,965 | TRF Vol: 1,080,957 | Short Ratio: 65.3% | Off-exchange volume (dark pool + OTC)
May 6, 2026
short_volume
Short Volume: AGEN — 71.8% short (0.4M / 0.5M)
Short: 393,900 | Exempt: 0 | TRF Vol: 548,965 | Short Ratio: 71.8% | Off-exchange volume (dark pool + OTC)
Apr 21, 2026
short_volume
Short Volume: AGEN — 60.2% short (0.4M / 0.6M)
Short: 354,623 | Exempt: 7,957 | TRF Vol: 588,907 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer
Phase Phase 2 — TERMINATED
Mar 9, 2026
earnings_calendar
AGEN Q4 2025 Earnings After Market Close — 2026-03-09
Dec 4, 2025
Enforcement
Medpace, Inc. v. Agenus Inc. et al.
Court ruling from District Court, S.D. New York. Docket: 1:25-cv-04179